Glucotrack, Inc.
Close on Oct 19, 2026
- Market cap
- $3.43M
- P/E (TTM)
- 0.0
- Dividend yield
- –
About Glucotrack
Surgical & Medical Instruments & Apparatus, SIC 3841
Glucotrack, Inc. is a medical device company focused on developing an implantable continuous blood glucose monitoring system, the Glucotrack CBGM. Designed for individuals with Type 1 diabetes as well as individuals with Type 2 diabetes who use insulin or are at risk for hypoglycemia, the system requires no additional wearable component. The device uses an intravascular design featuring a subcutaneously implanted unit connected to a lead inserted directly into a blood vessel to provide continuous blood glucose measurements. The company also investigates glucose sensing in the epidural space for patients considering spinal cord stimulation.
Glucotrack operates out of its principal executive offices in Rutherford, New Jersey, and holds ISO 13485 quality system certification. Development and manufacturing activities for the implantable system components are supported by specialized contract design and manufacturing partners. The company has conducted clinical research activities in the United States and Australia.
Summary of the business section of Glucotrack's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Glucotrack, Inc.
- Founded
- 2010
- Headquarters
- Rutherford, NJ
- Address
- 301 Rt 17 North, Suite 800 07070
- Phone
- 972 (8) 675-7878
- Website
- glucotrack.com
- Employees
- 15, Dec 31, 2025
- Industry
- Surgical & Medical Instruments & Apparatus
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- FAHN KANNE & CO. GRANT THORNTON ISRAEL, Tel-Aviv, Israel
Stock & identifiers
- Ticker
- GCTK
- Exchange
- Nasdaq
- IPO date
- Apr 25, 2013
- Shares outstanding
- 11M, Aug 14, 2026
- Public float
- $5.40M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-15 reverse, Aug 31, 2026; 1-for-60 reverse, Aug 14, 2025; 1-for-60 reverse, Jun 16, 2025; 1-for-20 reverse, Feb 4, 2025; 1-for-5 reverse, Aug 13, 2024; 1-for-5 reverse, May 20, 2024; 77-for-1, Aug 16, 2021; 1-for-13 reverse, Aug 13, 2021
- SEC CIK
- 1506983
- CUSIP
- 45824Q887
- ISIN
- US45824Q8877
- LEI
- 549300FJ98RZ4G4ULL57
- EIN
- 98-0668934
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Paul Goode | Chief Executive Officer, Director | 339 |
| Peter C. Wulff | Chief Financial Officer | – |
| Andrew K. Balo | Director | 4,692 |
| Luis Malave | Director | 4,058 |
| Brendel Victoria Carr | Director | – |
| Erin Catherine Carter | Director | 2,148 |
| John Ballantyne | Director | 2,747,717 |
| Robert Fischell | Director | 2,045 |
| Allen Danzig | Director | 1,922 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Paul V. Goode | $394.10K | $394.10K | $500.00K | $0 | – |
| FY2024 Paul V. Goode | $350.00K | $349.64K | – | $5 | – |
| FY2023 Paul V. Goode | $356.24K | $225.00K | $220.66K | $19 | – |
| FY2022 Paul V. Goode | $485.69K | $200.64K | $175.00K | $141 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had fifteen full-time employees.”
Corporate history
Events identified from SEC filings